Axel Pahl

Axel Pahl

Auto-generated profile, based on publicly available information

Axel Pahl

Compound Management and Screening Center (COMAS), Max Planck Institute of Molecular Physiology, Otto-Hahn-Straße 11, 44227 Dortmund, Germany

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Cell Chemical Biology
Verified
Journal Article
Closed access
APAxel Pahl
Axel Pahl
BSBeate Schölermann
Beate Schölermann
PLPhilipp Lampe
Philipp Lampe
MRMarion Rusch
Marion Rusch
MDMark Dow
Mark Dow
SZSlava Ziegler
Slava Ziegler

13 October 2022 in ChemBioChem
Verified
Journal Article
Open access
BSBeate Schölermann
Beate Schölermann
JBJana Bonowski
Jana Bonowski
MGMichael Grigalunas
Michael Grigalunas
ABAnnina Burhop
Annina Burhop
YXYusheng Xie
Yusheng Xie
SZSlava Ziegler
Slava Ziegler
Profiling approaches have been increasingly employed for the characterization of disease‐relevant phenotypes or compound perturbation as they provide a broad, unbiased view on impaired cellular states. We report that morphological profiling using the cell painting assay (CPA) can detect modulators of de novo pyrimidine biosynthesis and of dihydroorotate dehydrogenase (DHODH) in particular. The CPA can differentiate between impairment of pyrimidine and folate metabolism, which both affect cellular nucleotide pools. The identified morphological signature is shared by inhibitors of DHODH and the functionally tightly coupled complex III of the mitochondrial respiratory chain as well as by UMP synthase, which is downstream of DHODH. The CPA appears to be particularly suited for the detection of DHODH inhibitors at the site of their action in cells. As DHODH is a validated therapeutic target, the CPA will enable unbiased identification of DHODH inhibitors and inhibitors of de novo pyrimidine biosynthesis for biological research and drug discovery.

13 October 2022 in Chemistry – A European Journal
Verified
Journal Article
Open access
MGMichael Grigalunas
Michael Grigalunas
SPSohan Patil
Sohan Patil
AKAdrian Krzyzanowski
Adrian Krzyzanowski
APAxel Pahl
Axel Pahl
JFJana Flegel
Jana Flegel
HWHerbert Waldmann
Herbert Waldmann
Pseudo‐natural products (pseudo‐NPs) are de novo combinations of natural product (NP) fragments that define novel bioactive chemotypes. For their discovery, new design principles are being sought. Previously, pseudo‐NPs were synthesized by the combination of fragments originating from biosynthetically unrelated NPs to guarantee structural novelty and novel bioactivity. We report the combination of fragments from biosynthetically related NPs in novel arrangements to yield a novel chemotype with activity not shared by the guiding fragments. We describe the synthesis of the polyketide pseudo‐NP grismonone and identify it as a structurally novel and potent inhibitor of Hedgehog signaling. The insight that the de novo combination of fragments derived from biosynthetically related NPs may also yield new biologically relevant compound classes with unexpected bioactivity may be considered a chemical extension or diversion of existing biosynthetic pathways and greatly expands the opportunities for exploration of biologically relevant chemical space by means of the pseudo‐NP principle.

3 April 2024 in Advanced Science
Verified
Journal Article
Open access
LWLin Wang
Lin Wang
FYFurkan Yilmaz
Furkan Yilmaz
OYOkan Yildirim
Okan Yildirim
BSBeate Schölermann
Beate Schölermann
SBSukdev Bag
Sukdev Bag
HWHerbert Waldmann
Herbert Waldmann
The pseudo‐natural product (pseudo‐NP) concept aims to combine NP fragments in arrangements that are not accessible through known biosynthetic pathways. The resulting compounds retain the biological relevance of NPs but are not yet linked to bioactivities and may therefore be best evaluated by unbiased screening methods resulting in the identification of unexpected or unprecedented bioactivities. Herein, various NP fragments are combined with a tricyclic core connectivity via interrupted Fischer indole and indole dearomatization reactions to provide a collection of highly three‐dimensional pseudo‐NPs. Target hypothesis generation by morphological profiling via the cell painting assay guides the identification of an unprecedented chemotype for Aurora kinase inhibition with both its relatively highly 3D structure and its physicochemical properties being very different from known inhibitors. Biochemical and cell biological characterization indicate that the phenotype identified by the cell painting assay corresponds to the inhibition of Aurora kinase B.

24 October 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
JXJianing Xie
Jianing Xie
APAxel Pahl
Axel Pahl
AKAdrian Krzyzanowski
Adrian Krzyzanowski
AKAnna Krupp
Anna Krupp
JLJie Liu
Jie Liu
HWHerbert Waldmann
Herbert Waldmann
Monoterpene indole alkaloids (MIAs) are endowed with high structural and spatial complexity and characterized by diverse biological activities. Given this complexity‐activity combination in MIAs, rapid and efficient access to chemical matter related to and with complexity similar to these alkaloids would be highly desirable, since such compound classes might display novel bioactivity. We describe the design and synthesis of a pseudo‐natural product (pseudo‐NP) collection obtained by the unprecedented combination of MIA fragments through complexity‐generating transformations, resulting in arrangements not currently accessible by biosynthetic pathways. Cheminformatic analyses revealed that both the pseudo‐NPs and the MIAs reside in a unique and common area of chemical space with high spatial complexity‐density that is only sparsely populated by other natural products and drugs. Investigation of bioactivity guided by morphological profiling identified pseudo‐NPs that inhibit DNA synthesis and modulate tubulin. These results demonstrate that the pseudo‐NP collection occupies similar biologically relevant chemical space that Nature has endowed MIAs with.

4 July 2024 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
APAxel Pahl
Axel Pahl
OGOleksandr Grygorenko
Oleksandr Grygorenko
IKIvan S. Kondratov
Ivan S. Kondratov
HWHerbert Waldmann
Herbert Waldmann
Pseudo-natural products (PNPs) combine fragments derived from NPs in ways that are not found in nature, and may lead to the discovery of novel chemotypes for unexpected targets or the identification of unprecedented bioactivities.